About ipsen sa - IPSEY
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
IPSEY At a Glance
Ipsen SA
65, quai Georges Gorse
Boulogne-Billancourt, Ile-de-France 92650
| Phone | 33-1-58-33-50-00 | Revenue | 4.15B | |
| Industry | Pharmaceuticals: Major | Net Income | 500.52M | |
| Sector | Health Technology | 2025 Sales Growth | 12.781% | |
| Fiscal Year-end | 12 / 2026 | Employees | 5,535 | |
| View SEC Filings |
IPSEY Valuation
| P/E Current | 31.951 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.079 |
| Price to Sales Ratio | 2.809 |
| Price to Book Ratio | 2.27 |
| Price to Cash Flow Ratio | 9.07 |
| Enterprise Value to EBITDA | 8.841 |
| Enterprise Value to Sales | 2.652 |
| Total Debt to Enterprise Value | 0.104 |
IPSEY Efficiency
| Revenue/Employee | 749,510.332 |
| Income Per Employee | 90,428.965 |
| Receivables Turnover | 3.79 |
| Total Asset Turnover | 0.56 |
IPSEY Liquidity
| Current Ratio | 1.961 |
| Quick Ratio | 1.783 |
| Cash Ratio | 1.059 |
IPSEY Profitability
| Gross Margin | 70.584 |
| Operating Margin | 20.303 |
| Pretax Margin | 15.746 |
| Net Margin | 12.065 |
| Return on Assets | 6.757 |
| Return on Equity | 10.624 |
| Return on Total Capital | 8.031 |
| Return on Invested Capital | 9.261 |
IPSEY Capital Structure
| Total Debt to Total Equity | 22.383 |
| Total Debt to Total Capital | 18.289 |
| Total Debt to Total Assets | 13.989 |
| Long-Term Debt to Equity | 19.239 |
| Long-Term Debt to Total Capital | 15.721 |